Back

SGLT2i uptake among heart failure patients with reduced ejection fraction: ongoing prescriber hesitancy and how to address this.

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Chronic heart failure - SGLT2i Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Bing Wei Thaddeus Soh

Galway University Hospital, Galway (Ireland)

4 More presentations in this session

Presentation thumbnail
Cardiac sodium/hydrogen exchanger (NHE11) as a novel potential target for SGLT2i in heart failure
Doctor I. Gimenez Escamilla (Valencia, ES)
Abstract Slides
Presentation thumbnail
SGLT2 inhibitors in real-world patients with heart failure with preserved ejection fraction
Doctor R. Tarantini (Utrecht, NL)
Abstract Slides
Presentation thumbnail
The comparison of composite end-points between SGLT-2 inhibitors and placebo in diabetic patients with heart failure with mildly reduced ejection fraction: a meta-analysis of the literature
Associate Professor T. Cinar (Istanbul, TR)
Abstract Slides
Presentation thumbnail
Safety and efficacy of SGLT2 inhibitors in diabetic and non-diabetic heart failure patients, a meta-analysis of randomized controlled trials
Doctor A. Awad (Texas City, US)
Abstract Slides

Access the full session

Session thumbnail
Chronic heart failure - SGLT2i

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Breaking the barriers in guideline-directed medical therapy implementation in heart failure - discussion
thumbnail
Congress Presentation
The role of ICD therapy in heart failure in 2024. What is the holistic approach to treat heart failure?
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources